（图片仅供参考）
A “blockbuster drug” is a pharmaceutical product that generates more than $1 billion in annual sales for its manufacturer. This business model has historically driven the pharmaceutical industry, focusing research and development (R&D) on common, chronic conditions to maximize patent-protected revenue. This revenue funds further R&D for new drugs, creating a cycle of innovation and high profits.
在20世纪后期，重磅药物模式成为大型制药公司的主导战略。该模式依赖于研发并获得一种能够治疗常见慢性疾病的药物专利，例如高胆固醇（如立普妥）、胃酸反流（如奥美拉唑）或抑郁症（如百忧解）。一旦获得批准，公司便会发起大规模的市场营销活动，目标客户包括医生和消费者（在那些……）。 直接面向消费者 广告是合法的）。目标是实现广泛的处方使用并占据较大的市场份额。该药物的 专利 provides a period of market exclusivity, typically 20 years from the filing date, during which the company can charge high prices without competition from generic versions. The enormous profits generated during this period are used to recoup the substantial R&D investment—often exceeding $1 billion per approved drug—and to fund the development of the next generation of potential blockbusters. However, this model faces significant challenges. The “low-hanging fruit” of common diseases has largely been addressed, making new discoveries more difficult. Increased pressure from payers (governments and insurance companies) to control costs, and the looming “patent cliff” (when patents for multiple blockbuster drugs expire around the same time), have forced the industry to reconsider this strategy. Many companies are now shifting towards developing more specialized, high-value drugs for smaller patient populations, such as orphan drugs for rare diseases or personalized cancer therapies, which can command even higher prices per patient.
重磅药物模型
（如果日期未知或不相关，例如“流体力学”，则提供其显著出现的近似估计）
只有注册会员才能免费获取完整尺寸的图片和下载内容。
> 登录 <
